In patients presenting with cannabis hyperemesis syndrome (CHS), is haloperidol more effective compared to ondansetron for reducing pain and nausea?

BEEM Bottom Line

Why is this study important?

Cannabis Hyperemesis Syndrome (CHS) is increasingly common in the emergency department (ED), with chronic cannabis users presenting with episodic cycles of nausea and abdominal pain refractory to traditional anti-emetics. Case reports support the use of typical anti-psychotics (Haloperidol).[1] [2] This is the first trial to compare the effectiveness of haloperidol versus ondansetron for CHS.

Which, if any, threats to validity are most likely to have an impact on the results and how?

Thank you for your interest in the BEEM Journal!

To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.

If you would like a pre-view, click here to view some sample articles

Premium Content Available Through Subscription

BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.

A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.